Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Stroke

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 172 articles: HTML format

Single Articles

August 2024
1. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
   Dietary intervention for post-stroke dysphagia - Authors' reply.
   Lancet Neurol. 2024;23:764-765.
   PubMed    
   
   
   
2. SHIMIZU A, Yamaguchi K, Kunieda K, Ohno T, et al
   Dietary intervention for post-stroke dysphagia.
   Lancet Neurol. 2024;23:763-764.
   PubMed    
   
   
   
3. THE LANCET NEUROLOGY
   A real chance to reduce death and disability from stroke.
   Lancet Neurol. 2024;23:749.
   PubMed    
   
   
   July 2024
4. BOURCIER R, Marnat G, Dargazanli C, Zhu F, et al
   Safety and efficacy of stent retrievers plus contact aspiration in patients with acute ischaemic anterior circulation stroke and positive susceptibility vessel sign in France (VECTOR): a randomised, single-blind trial.
   Lancet Neurol. 2024;23:700-711.
   PubMed     Abstract available
   
   
   
5. ABDALKADER M, Nguyen TN
   Susceptibility vessel sign and endovascular stroke therapy.
   Lancet Neurol. 2024;23:653-654.
   PubMed    
   
   
   June 2024
6. GAO F, Tong X, Jia B, Wei M, et al
   Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
   Lancet Neurol. 2024 Jun 21:S1474-4422(24)00186.
   PubMed     Abstract available
   
   
   
7. CAMPBELL BCV
   Durable benefit of thrombectomy 6-24 h after stroke onset.
   Lancet Neurol. 2024 Jun 20:S1474-4422(24)00261.
   PubMed    
   
   
   
8. HUIJBERTS I, Pinckaers FME, Olthuis SGH, van Kuijk SMJ, et al
   Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands.
   Lancet Neurol. 2024 Jun 20:S1474-4422(24)00228.
   PubMed     Abstract available
   
   
   
9. PARSONS MW, Yogendrakumar V, Churilov L, Garcia-Esperon C, et al
   Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.
   Lancet Neurol. 2024 Jun 13:S1474-4422(24)00206.
   PubMed     Abstract available
   
   
   
10. TOYODA K
    Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?
    Lancet Neurol. 2024 Jun 13:S1474-4422(24)00258.
    PubMed    
    
    
    
11. ALI M, van Etten ES, Akoudad S, Schaafsma JD, et al
    Haemorrhagic stroke and brain vascular malformations in women: risk factors and clinical features.
    Lancet Neurol. 2024;23:625-635.
    PubMed     Abstract available
    
    
    
12. THE LANCET NEUROLOGY
    Forging ahead in haemorrhagic stroke research.
    Lancet Neurol. 2024;23:545.
    PubMed    
    
    
    
13. SISODIYA SM, Gulcebi MI, Fortunato F, Mills JD, et al
    Climate change and disorders of the nervous system.
    Lancet Neurol. 2024;23:636-648.
    PubMed     Abstract available
    
    
    May 2024
14. OLAVARRIA VV
    Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00208.
    PubMed    
    
    
    
15. ZONNEVELD TP, Vermeer SE, van Zwet EW, Groot AED, et al
    Safety and efficacy of active blood-pressure reduction to the recommended thresholds for intravenous thrombolysis in patients with acute ischaemic stroke in the Netherlands (TRUTH): a prospective, observational, cluster-based, parallel-group study.
    Lancet Neurol. 2024 May 15:S1474-4422(24)00177.
    PubMed     Abstract available
    
    
    
16. SARFO FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, et al
    The African Stroke Organization Conference 2023.
    Lancet Neurol. 2024;23:459-460.
    PubMed    
    
    
    
17. CORTESE I, Norato G, Harrington PR, Usher T, et al
    Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials.
    Lancet Neurol. 2024;23:534-544.
    PubMed     Abstract available
    
    
    
18. PELLINEN J, Foster EC, Wilmshurst JM, Zuberi SM, et al
    Improving epilepsy diagnosis across the lifespan: approaches and innovations.
    Lancet Neurol. 2024;23:511-521.
    PubMed     Abstract available
    
    
    April 2024
19. YASSI N, Zhao H, Churilov L, Wu TY, et al
    Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trial.
    Lancet Neurol. 2024 Apr 19:S1474-4422(24)00128.
    PubMed     Abstract available
    
    
    
20. 
    Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial.
    Lancet Neurol. 2024 Apr 17:S1474-4422(24)00096.
    PubMed     Abstract available
    
    
    
21. GUSTAVSSON EK, Follett J, Trinh J, Barodia SK, et al
    RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Lancet Neurol. 2024 Apr 10:S1474-4422(24)00121.
    PubMed     Abstract available
    
    
    
22. LABEIT B, Michou E, Trapl-Grundschober M, Suntrup-Krueger S, et al
    Dysphagia after stroke: research advances in treatment interventions.
    Lancet Neurol. 2024;23:418-428.
    PubMed     Abstract available
    
    
    
23. SEIFFGE DJ, Cancelloni V, Raber L, Paciaroni M, et al
    Secondary stroke prevention in people with atrial fibrillation: treatments and trials.
    Lancet Neurol. 2024;23:404-417.
    PubMed     Abstract available
    
    
    
24. SPOSATO LA, Andrade JG, Field TS
    Detection of atrial fibrillation in patients after stroke - Authors' reply.
    Lancet Neurol. 2024;23:336-337.
    PubMed    
    
    
    
25. SIONTIS KC, Noseworthy PA, Friedman PA
    Detection of atrial fibrillation in patients after stroke.
    Lancet Neurol. 2024;23:335-336.
    PubMed    
    
    
    
26. KANDEL A, Arjyal A, Karmacharya B, Gajurel B, et al
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:334.
    PubMed    
    
    
    
27. FEIGIN VL, Yaria J, Owolabi M
    Pragmatic solutions for the global burden of stroke - Authors' reply.
    Lancet Neurol. 2024;23:334-335.
    PubMed    
    
    
    
28. SCHLOGL M, Quinn TJ
    Pragmatic solutions for the global burden of stroke.
    Lancet Neurol. 2024;23:333-334.
    PubMed    
    
    
    
29. 
    Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Neurol. 2024;23:344-381.
    PubMed     Abstract available
    
    
    February 2024
30. MAZIGHI M, Kohrmann M, Lemmens R, Lyrer PA, et al
    Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
    Lancet Neurol. 2024;23:157-167.
    PubMed     Abstract available
    
    
    
31. GANESH A
    Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke.
    Lancet Neurol. 2024;23:125-127.
    PubMed    
    
    
    
32. SIMUNI T, Chahine LM, Poston K, Brumm M, et al
    A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research.
    Lancet Neurol. 2024;23:178-190.
    PubMed     Abstract available
    
    
    
33. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    January 2024
34. SHARMA M, Molina CA, Toyoda K, Bereczki D, et al
    Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Lancet Neurol. 2024;23:46-59.
    PubMed     Abstract available
    
    
    
35. KHATRI P
    Anticoagulants to prevent recurrent non-cardioembolic stroke.
    Lancet Neurol. 2024;23:3-5.
    PubMed    
    
    
    
36. ANDERSON CS
    Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage.
    Lancet Neurol. 2024;23:12-13.
    PubMed    
    
    
    December 2023
37. BRIGO F
    The (hi)story of stroke.
    Lancet Neurol. 2023;22:1110.
    PubMed    
    
    
    
38. UCHIYAMA S
    Anticoagulation in people with atrial fibrillation after intracranial haemorrhage.
    Lancet Neurol. 2023;22:1091-1092.
    PubMed    
    
    
    
39. ABBOTT A, Schott L, Gao L, Budincevic H, et al
    Carotid artery overtreatment in the USA.
    Lancet Neurol. 2023;22:1102-1103.
    PubMed    
    
    
    November 2023
40. KOPCZAK A, Stringer MS, van den Brink H, Kerkhofs D, et al
    Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial.
    Lancet Neurol. 2023;22:991-1004.
    PubMed     Abstract available
    
    
    
41. RUBIANO AM, Lee K
    Traumatic brain injury research: homogenising heterogeneity.
    Lancet Neurol. 2023;22:973-975.
    PubMed    
    
    
    
42. ADAMS D, Sekijima Y, Conceicao I, Waddington-Cruz M, et al
    Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
    Lancet Neurol. 2023;22:1061-1074.
    PubMed     Abstract available
    
    
    October 2023
43. MIRELMAN A, Rochester L, Simuni T, Hausdoff JM, et al
    Digital mobility measures to predict Parkinson's disease.
    Lancet Neurol. 2023 Oct 18:S1474-4422(23)00376.
    PubMed    
    
    
    
44. SPOSATO LA, Field TS, Schnabel RB, Wachter R, et al
    Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00326.
    PubMed     Abstract available
    
    
    
45. AL-SHAHI SALMAN R, Stephen J, Tierney JF, Lewis SC, et al
    Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00315.
    PubMed     Abstract available
    
    
    
46. KAMEL H
    Reassessing the implications of atrial fibrillation detected after stroke.
    Lancet Neurol. 2023 Oct 11:S1474-4422(23)00406.
    PubMed    
    
    
    
47. BRUSCA SB, Albert MA
    Balancing the scales of adversity: a socioecological approach to reducing the global burden of stroke and cardiovascular disease.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00386.
    PubMed    
    
    
    
48. WATKINS DA
    Policy priorities for preventing stroke-related mortality and disability worldwide.
    Lancet Neurol. 2023 Oct 9:S1474-4422(23)00387.
    PubMed    
    
    
    
49. FEIGIN VL, Owolabi MO
    Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission.
    Lancet Neurol. 2023 Oct 6:S1474-4422(23)00277.
    PubMed    
    
    
    
50. MARCUCCI M, Chan MTV, Smith EE, Absalom AR, et al
    Prevention of perioperative stroke in patients undergoing non-cardiac surgery.
    Lancet Neurol. 2023;22:946-958.
    PubMed     Abstract available
    
    
    
51. IZZY S, Grashow R, Radmanesh F, Chen P, et al
    Long-term risk of cardiovascular disease after traumatic brain injury: screening and prevention.
    Lancet Neurol. 2023;22:959-970.
    PubMed     Abstract available
    
    
    September 2023
52. HUGGER SS, Do TP, Ashina H, Goicochea MT, et al
    Migraine in older adults.
    Lancet Neurol. 2023 Sep 13:S1474-4422(23)00206.
    PubMed     Abstract available
    
    
    
53. LABEIT B, Michou E, Hamdy S, Trapl-Grundschober M, et al
    The assessment of dysphagia after stroke: state of the art and future directions.
    Lancet Neurol. 2023;22:858-870.
    PubMed     Abstract available
    
    
    
54. FENG W
    Diagnosis of post-stroke dysphagia: towards better treatment.
    Lancet Neurol. 2023;22:778-779.
    PubMed    
    
    
    
55. OSPEL JM, Goyal M
    Prehospital triage in acute stroke: which questions to ask?
    Lancet Neurol. 2023;22:771-772.
    PubMed    
    
    
    
56. D'GAMA AM, Mulhern S, Sheidley BR, Boodhoo F, et al
    Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study.
    Lancet Neurol. 2023;22:812-825.
    PubMed     Abstract available
    
    
    
57. GUTERUD M, Fagerheim Bugge H, Roislien J, Kramer-Johansen J, et al
    Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial.
    Lancet Neurol. 2023;22:800-811.
    PubMed     Abstract available
    
    
    August 2023
58. ODDO M, Taccone FS, Petrosino M, Badenes R, et al
    The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study.
    Lancet Neurol. 2023 Aug 28:S1474-4422(23)00271.
    PubMed     Abstract available
    
    
    
59. RIZIG M, Bandres-Ciga S, Makarious MB, Ojo OO, et al
    Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Lancet Neurol. 2023 Aug 23:S1474-4422(23)00283.
    PubMed     Abstract available
    
    
    
60. SOLOMON AJ, Arrambide G, Brownlee WJ, Flanagan EP, et al
    Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
    Lancet Neurol. 2023;22:750-768.
    PubMed     Abstract available
    
    
    
61. MEADOR KJ, Cohen MJ, Loring DW, Matthews AG, et al
    Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study.
    Lancet Neurol. 2023;22:712-722.
    PubMed     Abstract available
    
    
    
62. MAYNARD G, Kannan R, Liu J, Wang W, et al
    Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
    Lancet Neurol. 2023;22:672-684.
    PubMed     Abstract available
    
    
    
63. GILADI N, Alcalay RN, Cutter G, Gasser T, et al
    Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet Neurol. 2023;22:661-671.
    PubMed     Abstract available
    
    
    July 2023
64. ENGLISH C, Ramage E
    Secondary stroke prevention: more questions than answers.
    Lancet Neurol. 2023 Jul 25:S1474-4422(23)00278.
    PubMed    
    
    
    
65. SCHWARZBACH CJ, Eichner FA, Rucker V, Hofmann AL, et al
    The structured ambulatory post-stroke care program for outpatient aftercare in patients with ischaemic stroke in Germany (SANO): an open-label, cluster-randomised controlled trial.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00216.
    PubMed     Abstract available
    
    
    
66. DESBOROUGH MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al
    Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
    Lancet Neurol. 2023;22:557-567.
    PubMed     Abstract available
    
    
    
67. FRISONI GB, van der Flier W
    STRIVEing to describe small vessel disease.
    Lancet Neurol. 2023;22:548-549.
    PubMed    
    
    
    
68. GRANIT V, Benatar M, Kurtoglu M, Miljkovic MD, et al
    Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Lancet Neurol. 2023;22:578-590.
    PubMed     Abstract available
    
    
    
69. CORBOY JR, Fox RJ, Kister I, Cutter GR, et al
    Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
    Lancet Neurol. 2023;22:568-577.
    PubMed     Abstract available
    
    
    
70. MEISEL A
    Are CAR T cells the answer to myasthenia gravis therapy?
    Lancet Neurol. 2023;22:545-546.
    PubMed    
    
    
    June 2023
71. VAN DER MERWE J
    Stroke care quality-why recognition matters.
    Lancet Neurol. 2023;22:471.
    PubMed    
    
    
    
72. HAYWARD KS, Bernhardt J
    Aspiring to restore arm and hand function after stroke.
    Lancet Neurol. 2023;22:464-465.
    PubMed    
    
    
    May 2023
73. DUERING M, Biessels GJ, Brodtmann A, Chen C, et al
    Neuroimaging standards for research into small vessel disease-advances since 2013.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00131.
    PubMed     Abstract available
    
    
    
74. KOEMANS EA, Chhatwal JP, van Veluw SJ, van Etten ES, et al
    Progression of cerebral amyloid angiopathy: a pathophysiological framework.
    Lancet Neurol. 2023 May 23:S1474-4422(23)00114.
    PubMed     Abstract available
    
    
    
75. HOWARD JF JR, Bresch S, Genge A, Hewamadduma C, et al
    Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Neurol. 2023;22:395-406.
    PubMed     Abstract available
    
    
    
76. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Lancet Neurol. 2023;22:383-394.
    PubMed     Abstract available
    
    
    
77. KASKI D, Koohi N, Haider S, Chandratheva A, et al
    The hyperacute vestibular syndrome: ear or brain?
    Lancet Neurol. 2023;22:377-378.
    PubMed    
    
    
    April 2023
78. WU S, Anderson CS
    Antiplatelets for secondary stroke prevention in China.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00130.
    PubMed    
    
    
    
79. PAN Y, Meng X, Yuan B, Johnston SC, et al
    Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Lancet Neurol. 2023 Apr 27:S1474-4422(23)00113.
    PubMed     Abstract available
    
    
    
80. LAVALLEE PC, Charles H, Albers GW, Caplan LR, et al
    Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study.
    Lancet Neurol. 2023;22:320-329.
    PubMed     Abstract available
    
    
    
81. SAMUELS N, van de Graaf RA, Mulder MJHL, Brown S, et al
    Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.
    Lancet Neurol. 2023;22:312-319.
    PubMed     Abstract available
    
    
    
82. BERNHARDT J, Corbett D, Dukelow S, Savitz S, et al
    The International Stroke Recovery and Rehabilitation Alliance.
    Lancet Neurol. 2023;22:295-296.
    PubMed    
    
    
    
83. MAZIGHI M
    The quest for optimal blood pressure management after stroke.
    Lancet Neurol. 2023;22:285-286.
    PubMed    
    
    
    
84. FEIGIN VL, Brainin M, Martins SCO
    The polypill from a public-health perspective.
    Lancet Neurol. 2023;22:294-295.
    PubMed    
    
    
    March 2023
85. TSIVGOULIS G, Katsanos AH, Sandset EC, Turc G, et al
    Thrombolysis for acute ischaemic stroke: current status and future perspectives.
    Lancet Neurol. 2023 Mar 9:S1474-4422(22)00519.
    PubMed     Abstract available
    
    
    
86. REIFF T, Eckstein HH, Mansmann U, Hacke W, et al
    Treatment of asymptomatic carotid stenosis in SPACE-2 - Authors' reply.
    Lancet Neurol. 2023;22:198-199.
    PubMed    
    
    
    
87. SPENCE JD
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197-198.
    PubMed    
    
    
    
88. GOEL A, Soteriou I, Normando E
    Treatment of asymptomatic carotid stenosis in SPACE-2.
    Lancet Neurol. 2023;22:197.
    PubMed    
    
    
    
89. THORNTON CA, Moxley RT 3rd, Eichinger K, Heatwole C, et al
    Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
    Lancet Neurol. 2023;22:218-228.
    PubMed     Abstract available
    
    
    
90. LIPTON RB, Croop R, Stock DA, Madonia J, et al
    Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
    Lancet Neurol. 2023;22:209-217.
    PubMed     Abstract available
    
    
    February 2023
91. ALEMSEGED F, Nguyen TN, Coutts SB, Cordonnier C, et al
    Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice.
    Lancet Neurol. 2023 Feb 10:S1474-4422(22)00483.
    PubMed     Abstract available
    
    
    
92. MONICHE F, Cabezas-Rodriguez JA, Valverde R, Escudero-Martinez I, et al
    Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Lancet Neurol. 2023;22:137-146.
    PubMed     Abstract available
    
    
    
93. SAVITZ SI
    Intra-arterial bone marrow mononuclear cells for stroke.
    Lancet Neurol. 2023;22:105-106.
    PubMed    
    
    
    January 2023
94. GOYAL M, Singh N, Ospel J
    Clinical trials in stroke in 2022: new answers and questions.
    Lancet Neurol. 2023;22:9-10.
    PubMed    
    
    
    
95. JENSEN M, Suling A, Metzner A, Schnabel RB, et al
    Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial.
    Lancet Neurol. 2023;22:45-54.
    PubMed     Abstract available
    
    
    
96. DROUIN E, Pasquini M, Hautecoeur P
    The advent of stroke units.
    Lancet Neurol. 2023;22:31.
    PubMed    
    
    
    
97. CALVERT P, Gupta D, Lip GYH
    Early atrial fibrillation rhythm control after stroke.
    Lancet Neurol. 2023;22:3-4.
    PubMed    
    
    
    
98. PENSATO U, Romoli M, Lazzarin SM, Marcheselli S, et al
    The shortage of thrombolytics for stroke: a call for action.
    Lancet Neurol. 2023;22:28.
    PubMed    
    
    
    December 2022
99. ROALDSEN MB, Eltoft A, Wilsgaard T, Christensen H, et al
    Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
    Lancet Neurol. 2022 Dec 19:S1474-4422(22)00484.
    PubMed     Abstract available
    
    
    
100. MUIR KW
     Treatment of wake-up stroke: stick or TWIST?
     Lancet Neurol. 2022 Dec 19:S1474-4422(22)00515.
     PubMed    
     
     
     
101. THE LANCET NEUROLOGY
     Tackling the burden of stroke with primordial prevention.
     Lancet Neurol. 2022;21:1061.
     PubMed    
     
     
     
102. SOILEAU MJ, Aldred J, Budur K, Fisseha N, et al
     Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
     Lancet Neurol. 2022;21:1099-1109.
     PubMed     Abstract available
     
     
     November 2022
103. KUHLMANN T, Moccia M, Coetzee T, Cohen JA, et al
     Multiple sclerosis progression: time for a new mechanism-driven framework.
     Lancet Neurol. 2022 Nov 18:S1474-4422(22)00289.
     PubMed     Abstract available
     
     
     
104. CHURILOV L, Bivard A, Parsons MW
     Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply.
     Lancet Neurol. 2022;21:959.
     PubMed    
     
     
     
105. HUDAIB AR
     Tenecteplase versus alteplase for early treatment of ischaemic stroke.
     Lancet Neurol. 2022;21:959.
     PubMed    
     
     
     October 2022
106. HOU C, Lan J, Lin Y, Song H, et al
     Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China.
     Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00335.
     PubMed     Abstract available
     
     
     
107. GANESH A, Smith EE, Hill MD
     Remote ischaemic conditioning for stroke prevention.
     Lancet Neurol. 2022 Oct 27. pii: S1474-4422(22)00438.
     PubMed    
     
     
     
108. HOBEANU C, Lavallee PC, Charles H, Labreuche J, et al
     Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study.
     Lancet Neurol. 2022;21:889-898.
     PubMed     Abstract available
     
     
     
109. REIFF T, Eckstein HH, Mansmann U, Jansen O, et al
     Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial.
     Lancet Neurol. 2022;21:877-888.
     PubMed     Abstract available
     
     
     
110. BURTON A
     Valeria Caso: because women have strokes too.
     Lancet Neurol. 2022;21:873.
     PubMed    
     
     
     
111. CHRISTENSEN H
     Long-term disability after transient ischaemic attack or minor stroke.
     Lancet Neurol. 2022;21:859-860.
     PubMed    
     
     
     September 2022
112. PETER-DEREX L, Philippeau F, Garnier P, Andre-Obadia N, et al
     Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
     Lancet Neurol. 2022;21:781-791.
     PubMed     Abstract available
     
     
     
113. SYKES L, Akpalu A, Gordon C, Cullen L, et al
     Developing stroke care services in west Africa.
     Lancet Neurol. 2022;21:778-779.
     PubMed    
     
     
     
114. VAN DEN BERG SA, Uniken Venema SM, Reinink H, Hofmeijer J, et al
     Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial.
     Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00333.
     PubMed     Abstract available
     
     
     
115. SANDSET EC, Walter S, Song L
     The challenges of large-scale prehospital stroke trials.
     Lancet Neurol. 2022 Sep 1. pii: S1474-4422(22)00356.
     PubMed    
     
     
     August 2022
116. BRAININ M, Grisold W, Hankey GJ, Norrving B, et al
     Time to revise primary prevention guidelines for stroke and cardiovascular disease.
     Lancet Neurol. 2022;21:686-687.
     PubMed    
     
     
     June 2022
117. BAAK LM, Wagenaar N, van der Aa NE, Groenendaal F, et al
     Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
     Lancet Neurol. 2022;21:528-536.
     PubMed     Abstract available
     
     
     
118. GONZALEZ F, Ferriero DM
     Stem cells for perinatal stroke.
     Lancet Neurol. 2022;21:497-499.
     PubMed    
     
     
     
119. THE LANCET NEUROLOGY
     No area of stroke research should be left behind.
     Lancet Neurol. 2022;21:495.
     PubMed    
     
     
     May 2022
120. ROTHWELL PM
     20 years of improvement in stroke care: the rewards from finally funding more research.
     Lancet Neurol. 2022;21:402-404.
     PubMed    
     
     
     April 2022
121. BIVARD A, Zhao H, Churilov L, Campbell BCV, et al
     Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
     Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00171.
     PubMed     Abstract available
     
     
     
122. KVISTAD CE, Naess H, Helleberg BH, Idicula T, et al
     Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
     Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00124.
     PubMed     Abstract available
     
     
     
123. COUTTS SB, Yu AYX
     Tenecteplase for acute stroke: the thrombolysis puzzle.
     Lancet Neurol. 2022 Apr 29. pii: S1474-4422(22)00172.
     PubMed    
     
     
     
124. HILL G, Regan S, Francis R
     Research priorities to improve stroke outcomes.
     Lancet Neurol. 2022;21:312-313.
     PubMed    
     
     
     March 2022
125. BONATI LH, Jansen O, de Borst GJ, Brown MM, et al
     Management of atherosclerotic extracranial carotid artery stenosis.
     Lancet Neurol. 2022;21:273-283.
     PubMed     Abstract available
     
     
     February 2022
126. ZHAO J, Yuan F, Song C, Yin R, et al
     Safety and efficacy of three enteral feeding strategies in patients with severe stroke in China (OPENS): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
     Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00010.
     PubMed     Abstract available
     
     
     
127. DZIEWAS R
     Nutrition in acute stroke management: food for thought.
     Lancet Neurol. 2022 Feb 24. pii: S1474-4422(22)00078.
     PubMed    
     
     
     
128. GUTIERREZ J, Turan TN, Hoh BL, Chimowitz MI, et al
     Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment.
     Lancet Neurol. 2022 Feb 7. pii: S1474-4422(21)00376.
     PubMed     Abstract available
     
     
     
129. SAMARASEKERA U
     Jeyaraj Pandian: passionate about improving stroke care in India.
     Lancet Neurol. 2022;21:120.
     PubMed    
     
     
     January 2022
130. BAILLIEUL S, Dekkers M, Brill AK, Schmidt MH, et al
     Sleep apnoea and ischaemic stroke: current knowledge and future directions.
     Lancet Neurol. 2022;21:78-88.
     PubMed     Abstract available
     
     
     
131. PUY L, Cordonnier C
     Stroke research in 2021: insights into the reorganisation of stroke care.
     Lancet Neurol. 2022;21:2-3.
     PubMed    
     
     
     December 2021
132. FEIGIN VL
     Primary stroke prevention: useful thresholds?
     Lancet Neurol. 2021 Dec 16. pii: S1474-4422(21)00458.
     PubMed    
     
     
     November 2021
133. SCHREUDER FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, et al
     Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.
     Lancet Neurol. 2021;20:907-916.
     PubMed     Abstract available
     
     
     September 2021
134. PANDIAN JD, Sebastian IA
     Integrated approach to stroke burden: are we doing enough?
     Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00287.
     PubMed    
     
     
     
135. 
     Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
     Lancet Neurol. 2021 Sep 3. pii: S1474-4422(21)00252.
     PubMed     Abstract available
     
     
     
136. CASO V, Mosconi MG
     Lessons to be learned in intracerebral haemorrhage research.
     Lancet Neurol. 2021 Sep 2. pii: S1474-4422(21)00296.
     PubMed    
     
     
     
137. HOWARD DPJ, Rothwell PM
     Asymptomatic carotid stenosis and stroke risk - Authors' reply.
     Lancet Neurol. 2021;20:699.
     PubMed    
     
     
     
138. ABBOTT A
     Asymptomatic carotid stenosis and stroke risk.
     Lancet Neurol. 2021;20:698-699.
     PubMed    
     
     
     
139. ROTHWELL PM, Buchan AM
     A new thrombolytic drug for acute ischaemic stroke.
     Lancet Neurol. 2021;20:687-689.
     PubMed    
     
     
     
140. GUSEV EI, Martynov MY, Nikonov AA, Shamalov NA, et al
     Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
     Lancet Neurol. 2021;20:721-728.
     PubMed     Abstract available
     
     
     July 2021
141. BANDINI F, Vestito L, Filippi L
     Prehospital scales in acute ischaemic stroke management.
     Lancet Neurol. 2021;20:504.
     PubMed    
     
     
     
142. DUVEKOT MHC, Venema E, Kerkhoff H, Dippel DWJ, et al
     Prehospital scales in acute ischaemic stroke management - Authors' reply.
     Lancet Neurol. 2021;20:504-505.
     PubMed    
     
     
     June 2021
143. LI L, Poon MTC, Samarasekera NE, Perry LA, et al
     Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
     Lancet Neurol. 2021;20:437-447.
     PubMed     Abstract available
     
     
     
144. HAEUSLER KG, Kirchhof P, Kunze C, Tutuncu S, et al
     Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.
     Lancet Neurol. 2021;20:426-436.
     PubMed     Abstract available
     
     
     
145. CHENG X, Dong Q
     Towards individualised secondary prevention after intracerebral haemorrhage.
     Lancet Neurol. 2021;20:411-413.
     PubMed    
     
     
     
146. WASSERLAUF J, Volgman AS
     Monitoring for atrial fibrillation after stroke.
     Lancet Neurol. 2021;20:410-411.
     PubMed    
     
     
     May 2021
147. SAMARASEKERA U
     Michael Moskowitz: solving the puzzle of migraine.
     Lancet Neurol. 2021 May 17. pii: S1474-4422(21)00141.
     PubMed    
     
     
     
148. JORDAN LC, DeBaun MR, Donahue MJ
     Advances in neuroimaging to improve care in sickle cell disease.
     Lancet Neurol. 2021;20:398-408.
     PubMed     Abstract available
     
     
     
149. HACHINSKI V, Avan A, Gilliland J, Oveisgharan S, et al
     A new definition of brain health.
     Lancet Neurol. 2021;20:335-336.
     PubMed    
     
     
     April 2021
150. WEAVER NA, Kuijf HJ, Aben HP, Abrigo J, et al
     Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.
     Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00060.
     PubMed     Abstract available
     
     
     
151. PANTONI L, Salvadori E
     Location of infarcts and post-stroke cognitive impairment.
     Lancet Neurol. 2021 Apr 23. pii: S1474-4422(21)00107.
     PubMed    
     
     
     
152. BEST JG, Ambler G, Wilson D, Lee KJ, et al
     Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from
     Lancet Neurol. 2021;20:294-303.
     PubMed     Abstract available
     
     
     
153. GREENBERG SM
     Cerebral microbleeds and prediction of intracranial haemorrhage.
     Lancet Neurol. 2021;20:252-254.
     PubMed    
     
     
     
154. ZIAI WC, Al-Kawaz M
     Blood pressure management after endovascular therapy.
     Lancet Neurol. 2021;20:248-249.
     PubMed    
     
     
     
155. LAUMANN TO, Ortega M, Hoyt CR, Seider NA, et al
     Brain network reorganisation in an adolescent after bilateral perinatal strokes.
     Lancet Neurol. 2021;20:255-256.
     PubMed    
     
     
     March 2021
156. SCHMIDT R, Hofer E
     Identifying novel genetic risk loci for lacunar stroke.
     Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00099.
     PubMed    
     
     
     
157. TRAYLOR M, Persyn E, Tomppo L, Klasson S, et al
     Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.
     Lancet Neurol. 2021 Mar 25. pii: S1474-4422(21)00031.
     PubMed     Abstract available
     
     
     
158. ENGELTER ST, Traenka C, Gensicke H, Schaedelin SA, et al
     Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.
     Lancet Neurol. 2021 Mar 22. pii: S1474-4422(21)00044.
     PubMed     Abstract available
     
     
     
159. HOWARD DPJ, Gaziano L, Rothwell PM
     Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.
     Lancet Neurol. 2021;20:193-202.
     PubMed     Abstract available
     
     
     
160. VAN DIJCK JTJM, Kompanje EJO, Nederkoorn PJ, Peul WC, et al
     Advanced consent for acute stroke trials - Authors' reply.
     Lancet Neurol. 2021;20:170-171.
     PubMed    
     
     
     
161. SHAMY M, Dewar B, Niznick N, Nicholls S, et al
     Advanced consent for acute stroke trials.
     Lancet Neurol. 2021;20:170.
     PubMed    
     
     
     
162. SPENCE JD
     Treatment of asymptomatic carotid stenosis.
     Lancet Neurol. 2021;20:163-165.
     PubMed    
     
     
     February 2021
163. MAZIGHI M, Richard S, Lapergue B, Sibon I, et al
     Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
     Lancet Neurol. 2021 Feb 26. pii: S1474-4422(20)30483.
     PubMed     Abstract available
     
     
     January 2021
164. DUVEKOT MHC, Venema E, Rozeman AD, Moudrous W, et al
     Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.
     Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30439.
     PubMed     Abstract available
     
     
     
165. GOYAL M, Marko M
     Optimising prehospital stroke triage in a changing landscape.
     Lancet Neurol. 2021 Jan 7. pii: S1474-4422(20)30488.
     PubMed    
     
     
     
166. TSIVGOULIS G, Katsanos AH
     Important advances in stroke research in 2020.
     Lancet Neurol. 2021;20:2-3.
     PubMed    
     
     
     December 2020
167. WU S, Anderson CS
     Healthy eating for secondary stroke prevention.
     Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30450.
     PubMed    
     
     
     
168. ENGLISH C, MacDonald-Wicks L, Patterson A, Attia J, et al
     The role of diet in secondary stroke prevention.
     Lancet Neurol. 2020 Dec 18. pii: S1474-4422(20)30433.
     PubMed     Abstract available
     
     
     
169. SILBERGLEIT R, Dickert NW
     Context and principles must drive alternatives to consent in emergency research.
     Lancet Neurol. 2020;19:968-969.
     PubMed    
     
     
     November 2020
170. THE LANCET NEUROLOGY
     A unified European action plan on stroke.
     Lancet Neurol. 2020 Nov 6. pii: S1474-4422(20)30409.
     PubMed    
     
     
     October 2020
171. MERETOJA A, Yassi N, Wu TY, Churilov L, et al
     Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
     Lancet Neurol. 2020 Oct 28. pii: S1474-4422(20)30369.
     PubMed     Abstract available
     
     
     
172. KOMPANJE EJO, van Dijck JTJM, Chalos V, van den Berg SA, et al
     Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.
     Lancet Neurol. 2020 Oct 21. pii: S1474-4422(20)30276.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Stroke is free of charge.